TABLE 1
FROM:
Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension
E Teijeira-Fernandez, S Eiras, L Grigorian-Shamagian, A Fernandez, B Adrio and J R Gonzalez-Juanatey
BACK TO ARTICLETable 1. Baseline characteristics of the hypertensive and the non-hypertensive groups
| All subjects | With HT (n=84) | Without HT (n=32) | P* | |
|---|---|---|---|---|
| Demographics | ||||
| Male (%) | 67 | 63 | 78 | 0.12 |
| Age (years) | 70.3 7.9 | 70.76.9 | 69.010.1 | 0.30 |
| Comorbidities and risk factors | ||||
| Current smoker (%) | 8 | 10 | 4 | 0.23 |
| Body mass index (kg/m2) | 28.84.1 | 27.64.2 | 29.23.9 | 0.06 |
| Diabetes mellitus (%) | 36 | 41 | 24 | 0.13 |
| Coronary artery disease (%) | 61 | 66 | 48 | 0.10 |
| Heart failure (%) | 30 | 32 | 25 | 0.45 |
| LVEF (%) | 6015 | 6014 | 6015 | 0.91 |
| Treatment prior to surgery | ||||
| ACEIs/ARBs (%) | 41 | 43 | 35 | 0.63 |
| Statins (%) | 40 | 43 | 32 | 0.48 |
| Beta blockers (%) | 36 | 38 | 32 | 0.71 |
| Calcium channel blockers (%) | 27 | 37 | 3 | 0.001 |
| Laboratory findings | ||||
| Urea (mg per 100 ml) | 5727 | 5723 | 5837 | 0.82 |
| Creatinine (mg per 100 ml) | 1.10.3 | 1.10.4 | 1.10.3 | 0.37 |
| Triglycerides (mg per 100 ml) | 11950 | 12651 | 10242 | 0.023 |
| Cholesterol (mg per 100 ml) | 18143 | 17839 | 18344 | 0.41 |
| HDL cholesterol (mg per 100 ml) | 3713 | 3613 | 3813 | 0.58 |
| LDL cholesterol (mg per 100 ml) | 10835 | 10636 | 11232 | 0.53 |
| EAT adiponectin mRNA (a.u.) | 14.43.6 | 14.03.6 | 15.33.6 | 0.06 |
| SAT adiponectin mRNA (a.u.) (n=85) | 15.34.4 | 15.34.2 | 15.35.0 | >0.99 |
Abbreviations: a.u., arbitrary units; ACEIs, angiotensin converter enzyme inhibitors; ARBs, angiotensin receptor blockers; EAT, epicardial adipose tissue; HDL, high-density lipoprotein; HT, arterial hypertension; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; SAT, subcutaneous adipose tissue.
Values expressed as means.d.
* P-value referred to the comparison between HT and non-HT groups.
